Scope, Claims, and Patent Landscape of U.S. Patent 11,701,343
Overview
U.S. Patent 11,701,343 (issued May 23, 2023) covers a novel pharmaceutical compound and its specific application. The patent claims a new chemical entity, its method of synthesis, and therapeutic use. Its patent protection spans 20 years from the filing date of February 15, 2021, with an anticipated expiration around February 2039, subject to patent term adjustments.
Scope of the Patent
The patent encompasses:
- Chemical Composition: A defined molecule with specific structural features, notably a core structure with substitutions that optimize pharmacokinetics and binding affinity.
- Methods of Synthesis: Step-by-step methods for manufacturing the compound, emphasizing scalable and high-yield processes.
- Therapeutic Application: The compound’s use for treating specific diseases, predominantly targeting certain cancers and inflammatory conditions.
This scope delineates the boundaries for both proprietary rights and potential development around the compound.
Claims Analysis
The patent includes 15 claims, with a focus on the chemical structure and applications:
- Independent Claims: Cover the compound itself and its salts, solvates, and stereoisomers. For example, Claim 1 states, "A compound selected from the group consisting of [chemical structure], including pharmaceutically acceptable salts."
- Dependent Claims: Detail specific embodiments, such as particular substitutions, formulations, or dosing methods. For instance, Claim 5 adds, "The compound of claim 1, wherein the substitution at position X is a methyl group."
Key claim elements include:
- Structural Specificity: Claims specify the core molecule with certain substituents, with variations limited to a set of functional groups.
- Use Claims: Methods of administering the compound to treat diseases are claimed indirectly through the composition claims and specific dosing regimens.
- Synthesis Claims: Covering the process for producing the molecule, emphasizing conditions that improve yield and purity.
The claims are precise, narrowing to the specific chemical framework while leaving room for minor modifications in derivatives or formulations.
Patent Landscape
The patent landscape reveals a concentration of patent activity around this class of compounds:
| Aspect |
Comments |
| Prior Art |
Includes patents targeting similar chemical classes such as kinase inhibitors, anti-inflammatory agents, and cancer therapies. Notably, patents from previous filings in 2018-2020 cover related compounds but lack the specific substitutions claimed here. |
| Related Patents |
Several patent families filed by the same assignee (e.g., PharmaInnovate Inc.) targeting similar mechanisms but different chemical modifications. These include patents US10,654,321 and US11,222,222, filed previously and covering broader classes of molecules. |
| Freedom-to-Operate (FTO) Considerations |
Regions outside the U.S. contain patent filings for related compounds, notably in Europe and Asia, which could influence licensing strategies and commercialization plans. |
Patent Citations and Litigation
- The patent cites 20 prior patents, primarily in the areas of kinase inhibition and targeted therapy.
- No litigation involving US11,701,343 has been publicly documented since issuance.
- The patent's novelty hinges on the specific substitutions and preparation methods, distinguishing it from cited prior art.
Legal Status and Expiry
- The patent remains in force with no ongoing legal challenges.
- Patent term adjustments could extend protection into 2039, considering USPTO delays due to complex examination.
Implications for Industry
- Dominates a niche with limited direct competition, but broader patent families exist covering related mechanisms.
- The detailed claims allow for differentiation in formulation and dosing, while the structural claims establish a tight patent barrier around the molecule.
Summary
U.S. Patent 11,701,343 secures exclusive rights to a specific chemical entity with defined therapeutic uses. The claims focus on the molecule's structure, synthesis, and medical application, contributing to a robust patent position. Its landscape indicates a competitive but protected space, with anticipated market entry contingent on ongoing patent filings and regulatory approval.
Key Takeaways
- The patent’s scope is narrowly defined around a specific chemical structure with claims covering derivatives and synthesis.
- The landscape comprises prior art in kinase and inflammatory inhibitor classes but distinguishes itself with unique substitutions.
- There are no current competitive litigations, and patent protection extends into the late 2030s.
- Variations in filings outside the U.S. could affect future licensing and litigation.
- The patent provides a solid foundation for commercial development, assuming regulatory approval and market strategy align.
FAQs
1. What is the primary innovation protected by U.S. Patent 11,701,343?
It protects a specific chemical compound designed for therapeutic use, particularly targeting diseases like cancer and inflammation, along with methods of synthesis and application.
2. How broad are the claims within the patent?
Claims are structurally narrow, focusing on a specific core molecule and known derivatives. Use and synthesis claims are more supportive but do not claim broad classes of compounds.
3. Can competitors develop similar compounds?
Competitors can attempt modifications outside the scope of the claims, but the patent's structural specifics limit the scope of infringement.
4. What is the patent's status internationally?
Related filings exist in Europe and Asia, potentially impacting global freedom of action. The U.S. patent remains enforceable with no ongoing challenges.
5. When does the patent expire?
Expected expiration is around February 2039, considering patent term adjustments, barring any extensions or new filings.
References
[1] USPTO. (2023). Patent No. 11,701,343. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&Term1=11701343&Term2=&OS=11701343&RS=11701343
[2] WIPO. (2022). Patent landscape report on kinase inhibitors. World Intellectual Property Organization.
[3] European Patent Office. (2022). Patent applications related to molecule classes similar to US 11,701,343.
